Salt of EGFR inhibitor, crystalline form and uses thereof
AssigneeSunshine Lake Pharma Co., Ltd.
InventorsBing Liu, Weihong Zhang, Yingjun Zhang
Life of this patent
Estimating the term…
Abstract
The invention relates to a salt, a hydrate or a crystalline form of an EGFR inhibitor, and use thereof. Specifically it relates to 4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-[3-[(1R,6S)-2,5-dioxa-8-azabicyclo [4.3.0] nonan-8-yl] propoxy] quinazoline dimethanesulfonate, hydrate and a crystalline form thereof; the invention also relates to a preparation method of the crystalline form disclosed herein, a pharmaceutical composition containing the crystalline form, and uses thereof for treating proliferative disorders.
Claims20
A compound having Formula (I):
A hydrate of a compound having formula (I).
A crystalline form of a monohydrate of a compound having formula (I):
- wherein the crystalline form is form I having one or more of following characteristics:
- i) an X-ray powder diffraction (XRPD) pattern comprising peaks expressed in degrees 2θ at 14.88°±0.2°, 18.05°±0.2°, 20.84°±0.2°, 21.34°±0.2°, 24.39°±0.2° and 25.18°±0.2°;
- or/and
- ii) the following structure parameters analyzed from monocrystalline:
- Crystallographic System:
- monoclinic system
- Space Groups:
- C2/c;
- Cell Parameters:
- a = 27.3004(5) Å, α = 90°,
- b = 16.2882(3) Å, β = 103.3439(17)°,
- c = 14.3529(2) Å, γ = 90°;
- Volume:
- 6210.01(18) Å3;
- Molecules number of
- 8.
- each unit cell (Z):
Dependencies are inferred from the claim text.